COGENT BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.47 USD | -3.24% |
|
-5.68% | +27.04% |
| May. 07 | Cogent Biosciences Q1 Loss Widens | MT |
| May. 07 | Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to the Unum Therap...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Companyâs clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
7.47
USD
Average target price
17.18
USD
Spread / Average Target
+130.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.04% | 714M | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| +0.90% | 22.28B | |
| -11.90% | 22.41B | |
| -5.34% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- COGT Stock
- News Cogent Biosciences, Inc.
- Transcript : Unum Therapeutics Inc., Q2 2019 Earnings Call, Aug 12, 2019
